MIR192, microRNA 192, 406967

N. diseases: 173; N. variants: 1
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Diabetes Mellitus, Non-Insulin-Dependent
0.360 Biomarker disease BEFREE The aim of this study was the evaluation of copy number variations (CNVs) of hsa-miR-93, hsa-miR-122, hsa-miR-192 in CAD patients with or without T2DM. 31392905 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.360 Biomarker disease BEFREE A total of 68 patients with type 2 DM and 11 healthy subjects were enrolled in a cross-sectional study and assessed concerning urinary albumin:creatinine ratio (UACR), urinary <i>N</i>-acetyl-β-D-glucosamininidase (NAG), urinary kidney injury molecule-1, urinary nephrin, podocalyxin, synaptopodin, estimated glomerular filtration rate (eGFR), urinary miRNA21, miRNA124, and miRNA192. 29279420 2018
Diabetes Mellitus, Non-Insulin-Dependent
0.360 AlteredExpression disease BEFREE It was observed that there was higher miR‑377 expression and lower miR‑192 expression in T2D patients with and without DN compared with healthy controls (P<0.05). miR‑377 was higher in the normoalbuminuric group and gradually increased in the microalbuminuric and macroalbuminuric groups (P<0.05), whereas miR‑192 was lower in the macroalbuminuric group compared with the normoalbuminuric group (P<0.05). 29845236 2018
Diabetes Mellitus, Non-Insulin-Dependent
0.360 Biomarker disease BEFREE This miRNA is a 3' arm derived from the same pre-miRNA as miR-192 (miR-192-5p) implicated in type 2 diabetes, liver disease and cancers, and is predicted to target key genes in lipid metabolism. 26747651 2016
Diabetes Mellitus, Non-Insulin-Dependent
0.360 Biomarker disease BEFREE CONCLUSIONS Genes including TAF1 and MAFK, and miRNAs including hsa-miR-29a, hsa-miR-192, and hsa-miR-144 might be potential target genes and important miRNAs for IFG and T2DM. 27906902 2016
Diabetes Mellitus, Non-Insulin-Dependent
0.360 Biomarker disease BEFREE The clinical significance of five potential miRs (miR-21, miR-29a, miR-29b, miR-29c and miR192) in type 2 Diabetes Mellitus (T2DM) patients who have existing diabetic retinopathy with differential Albumin:Creatinine Ratio (ACR) and estimated Glomerular Filtration Rate (eGFR) was performed using quantitative RT-PCR analysis. 27279796 2016
Diabetes Mellitus, Non-Insulin-Dependent
0.360 Biomarker disease CTD_human Cross-sectional studies disclosed a marked increase of miR-140-5p, miR-142-3p, and miR-222 and decreased miR-423-5p, miR-125b, miR-192, miR-195, miR-130b, miR-532-5p, and miR-126 in T2D patients. 24478399 2014
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.340 Biomarker disease BEFREE Conclusions: Our findings indicate that miR-192-3p is a regulator of HBV infection and may play a potential role in hepatocellular carcinoma. 30180281 2019
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.340 Biomarker disease BEFREE The three miRNAs mir-21, mir-122, mir-192, together with AFP, are biomarkers that may be applied to improve diagnostics of HCC in HBV patients, especially in HBV-related LC patients with normal AFP levels or HCC patients with small tumor sizes. 29672637 2018
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.340 Biomarker disease CTD_human "Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human." 28545106 2017
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.340 Biomarker disease BEFREE In circulating vesicles, miRNA-192 (HBV: <i>p <</i> 0.0001; HCV: <i>p <</i> 0.0001), -200b (HBV: <i>p <</i> 0.0001; HCV: <i>p <</i> 0.0001), -92a (HBV: <i>p <</i> 0.0001; HCV: <i>p <</i> 0.0001), and -150 (HBV: <i>p</i> = 0.0016; HCV: <i>p</i> = 0.004) displayed a significant down-regulation in both HBV and HCV patients. 28232800 2017
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.340 AlteredExpression disease BEFREE These results indicated that persistent HBV infection might trigger NER impairment in part through upregulation of miR-192, which suppressed the levels of ERCC3 and ERCC4. 21672525 2011
CUI: C0022660
Disease: Kidney Failure, Acute
Kidney Failure, Acute
0.320 Biomarker disease CTD_human A scrutiny of circulating microRNA biomarkers for drug-induced tubular and glomerular injury in rats. 30682439 2019
CUI: C0022660
Disease: Kidney Failure, Acute
Kidney Failure, Acute
0.320 AlteredExpression disease BEFREE Additionally, normalization of miRNA (miR-192-5p and miR-140-5p) implicated in AKI, poly(ADP-ribose) polymerase 1 levels, antiapoptotic signaling, intracellular NAD<sup>+</sup>, and mitochondrial oxidative phosphorylation were observed in the treatment group. 31532243 2019
CUI: C0022660
Disease: Kidney Failure, Acute
Kidney Failure, Acute
0.320 AlteredExpression disease BEFREE Plasma miR-192 expression was induced in a time-dependent manner after IRI in rats and patients with AKI after cardiac surgery, comparably to the kidney injury development and recovery process, and may be useful for the detection of AKI. 28035621 2017
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases
0.310 Biomarker group BEFREE MiR-192 is regarded as a potential noninvasive biomarker for kidney disease. 30808829 2019
CUI: C0860207
Disease: Drug-Induced Liver Disease
Drug-Induced Liver Disease
0.310 Biomarker phenotype BEFREE It has been demonstrated that miR-122 and miR-192, which are liver enriched, could be potential biomarkers of DILI; however, these miRNAs cannot discern types of injuries. 30125006 2018
CUI: C0860207
Disease: Drug-Induced Liver Disease
Drug-Induced Liver Disease
0.310 Biomarker phenotype CTD_human Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease. 28483554 2017
CUI: C0860207
Disease: Drug-Induced Liver Disease
Drug-Induced Liver Disease
0.310 Biomarker phenotype CTD_human "Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human." 28545106 2017
CUI: C0860207
Disease: Drug-Induced Liver Disease
Drug-Induced Liver Disease
0.310 Biomarker phenotype CTD_human Recently, circulating microRNAs (miRNAs) such as miR-122 and miR-192 have emerged as promising biomarkers of liver injury in preclinical species and in DILI patients. 25359176 2015
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases
0.310 Biomarker group CTD_human Urinary microRNA profiling for identification of biomarkers after cisplatin-induced kidney injury. 24880025 2014
CUI: C0860207
Disease: Drug-Induced Liver Disease
Drug-Induced Liver Disease
0.310 Biomarker phenotype CTD_human Circulating microRNAs as potential markers of human drug-induced liver injury. 22045675 2011
CUI: C1565662
Disease: Acute Kidney Insufficiency
Acute Kidney Insufficiency
0.300 Biomarker disease CTD_human A scrutiny of circulating microRNA biomarkers for drug-induced tubular and glomerular injury in rats. 30682439 2019
CUI: C2609414
Disease: Acute kidney injury
Acute kidney injury
0.300 Biomarker disease CTD_human A scrutiny of circulating microRNA biomarkers for drug-induced tubular and glomerular injury in rats. 30682439 2019
CUI: C0019193
Disease: Hepatitis, Toxic
Hepatitis, Toxic
0.300 Biomarker disease CTD_human Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease. 28483554 2017